Real-life analysis of neoadjuvant-therapy-associated benefits for pathological complete response and survival in early breast cancer patients - role of trastuzumab in HER2+ BC and platinum in TNBC

BACKGROUND: Neoadjuvant therapy, which aims to achieve a pathological complete response (pCR) for better overall survival (OS) has several advantages for patients with early breast cancer (eBC) and subtypes of HER2-positive (HER2+) and triple-negative breast cancer (TNBC). However, there has been no...

Descripción completa

Detalles Bibliográficos
Autores principales: Chung, Wei-Pang, Yang, Chun-Ting, Yang, Shuen-Ru, Su, Ching-Yen, Su, Hsin-Wei, Liu, Shang-Yun, Ou, Huang-Tz
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9902925/
https://www.ncbi.nlm.nih.gov/pubmed/36761415
http://dx.doi.org/10.3389/fonc.2022.1022994

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9902925/
https://www.ncbi.nlm.nih.gov/pubmed/36761415
http://dx.doi.org/10.3389/fonc.2022.1022994

Ejemplares similares